EFFICACY AND SAFETY OF CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) RESULTS FROM A PHASE II GLOBAL TRIAL

被引：0

作者：

Ferreira, Carlos G. ^{[1
]}

Barrios, C. ^{[2
]}

Shaw, Alice T. ^{[3
]}

Shi, Yuankai ^{[4
]}

De Pas, Tommaso M. ^{[5
]}

Yang, Pan C. ^{[6
]}

Riely, Greg J. ^{[7
]}

Crino, Lucio ^{[8
]}

Iyer, Shrividya ^{[9
]}

Polli, Anna ^{[11
]}

Lanzalone, Silvana ^{[11
]}

Kim, Dong W. ^{[10
]}

机构：

[1] Inst Nacl Canc, Div Clin & Translat Res, Rio De Janeiro, Brazil

[2] Pucrs Sch Med, Dept Med, Porto Alegre, RS, Brazil

[3] Massachusetts Gen Hosp, Dept Thorac Oncol, Boston, MA 02114 USA

[4] Chinese Acad Med Sci Cams, Dept Med Oncol, Beijing, Peoples R China

[5] European Inst Oncol, Med Oncol Unit Resp Tract & Sarcomas, Milan, Italy

[6] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan

[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[8] S Maria Della Misericordia Hosp, Perugia, Italy

[9] Pfizer, Oncol, New York, NY USA

[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea

[11] Pfizer, Oncol, Milan, Italy

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S107 / S108

页数：2